Clinical Trial

Impact of the New Generation Anti-diabetic Drugs on Diabetic Retinopathy

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 20, 2026 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to test the impact of new-generation anti-diabetic drugs, such as SGLT2 inhibitors and DPP-4 inhibitors, on the development of diabetic retinopathy (DR). The study hypothesizes that these drugs have protective effects in diabetic retinopathy by delaying its incidence compared to older agents (including metformin) only. Early intervention is critical, as treatment options for advanced stages of DR are limited in terms of their ability to restore impaired vision and their high associated costs. By focusing on delaying the occurrence of diabetic retinopathy, the investigators aim to reduce the burden of DR and improve the quality of life for diabetic patients.
Trial Details
NCT Number NCT07351786
Lead Sponsor Sara A Belal
Conditions Diabetes (DM), Retinopathy, Diabetic, Diabetic Retinopathy (DR), Diabetic Retinopathy Associated With Type 2 Diabetes Mellitus
Enrollment 70 participants
Start Date 2025-08-01
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-01-20